The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
oxybutynin
oxybutynin · OXYBUTYNIN CHLORIDE 15 mg/1 · Tablet, Film Coated, Extended Release · Oral · Zydus Lifesciences Limited
NDC 70771-1088-01 · 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for oxybutynin (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $962.56 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA202332
- TE code
- AB
- Approval date
- Jun 26, 2017
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of oxybutynin (Tablet, Film Coated, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | OXYBUTYNIN CHLORIDE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NCS HealthCare of KY, LLC dba Vangard Labs | OXYBUTYNIN CHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| NCS HealthCare of KY, LLC dba Vangard Labs | OXYBUTYNIN CHLORIDE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | OXYBUTYNIN CHLORIDE 15 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | OXYBUTYNIN CHLORIDE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | OXYBUTYNIN CHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | OXYBUTYNIN CHLORIDE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | OXYBUTYNIN CHLORIDE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | OXYBUTYNIN CHLORIDE 15 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "oxybutynin — NDC 70771-1088-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70771108801.
Free to cite with attribution — see how the data is put together.